Clinical Trails Post

October 2024 clinical trial highlights

by Pulmonary Fibrosis Foundation
October 24, 2024
woman-researcher-at-work

In the October 2024 clinical trial highlights, we'll showcase just a few of the many trials that are open for enrollment and seeking volunteers. To view more available trials for various forms of interstitial lung disease, please visit the 🔍 PFF Clinical Trial Finder.


Seeking participants with pulmonary fibrosis, interstitial lung disease, lung fibrosis, idiopathic pulmonary fibrosis

Pulmonary Fibrosis Foundation Community Registry

Learn more about this study

 

 

Seeking participants with rheumatoid arthritis associated with interstitial lung disease

MOUNTAIN

  • Study ID: NCT06397677
  • Intervention: Blood or biological sample collection
  • Sponsor: University of Colorado, Denver
  • Study Contact: Tyna O’Connor (tyna.oconnor@cuanschutz.edu)

Learn more about this study

 

Seeking participants with idiopathic pulmonary fibrosis

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

Learn more about this study Learn more about this drug

 

Research Roundup

Since its founding in 2000, the PFF has led the charge to create a world without pulmonary fibrosis. We have done this by forging partnerships with other patient and provider organizations, research institutions, the pharmaceutical and biotech industries, and government agencies. 

Here is some of the latest news on PF and ILD research initiatives:

Happy anniversary to Esbriet® and OFEV®! 

These two medications were FDA-approved 10 years ago this month, and they were the first-ever approved medications for the treatment of idiopathic pulmonary fibrosis. It was a pivotal moment for people living with pulmonary fibrosis.

The availability of these two medications changed clinical care and energized research and development, and the research pipeline has grown stronger ever since. Now, there are over 40 phase 2 or higher clinical trials that are testing new medications, and they’re actively recruiting patients. Esbriet® and OFEV® would not be here today without patient participation in clinical trials.

Phase 3 idiopathic pulmonary fibrosis study meets its primary endpoints

In September 2024, Boehringer Ingelheim announced that the phase 3 clinical trial, FIBRONEER™-IPF, met its primary endpoint. A primary endpoint is the measurement that researchers use to determine if a medication or other intervention works as intended. In idiopathic pulmonary fibrosis (IPF) studies, forced vital capacity (FVC) is the primary endpoint. FVC is the measurement obtained when a patient completes a spirometry test (e.g., pulmonary function test).

The two approved antifibrotics were approved based on FVC, and current clinical trials are using this as the determination if a medication can lessen worsening lung function, or progression of lung fibrosis.

In the FIBRONEER trial, at 52 weeks those who had received the active medication in development had less lung function decline than those who received the placebo (i.e., non-active pills). The study will continue to follow and conduct further review on the "secondary endpoints" such as hospitalization, an episode of rapid worsening of a pulmonary condition known as acute exacerbations, and death; along with how many participants had side effects.

The trial achieving its endpoint marks a significant development in advancing care for patients living with IPF and demonstrates the important of research studies which support the development of improved therapies for pulmonary fibrosis and interstitial lung disease (ILD).

To learn more about clinical trials, review the PFF’s clinical trial guide and the PFF’s pulmonary function tests guide.